Axsome's FDA approval for Auvelity in Alzheimer's agitation, challenging Rexulti's market position. Summit Therapeutics tumbled nearly 20% after an apparent interim analysis miss for its cancer drug ivonescimab, while Esperion agreed to a $1.1 billion take-private deal by healthcare investor ArchiMed. The FDA's ODAC panel delivered a split verdict for AstraZeneca, rejecting camizestrant 6-3 while backing Truqap 7-1. Meanwhile, Moderna's Q1 revenues nearly tripled to $389 million, driven by international COVID vaccine sales offsetting U.S. declines.
Top Stories
Summit Therapeutics shares plunge 20% on ivonescimab interim analysis apparent miss
Summit Therapeutics' stock tumbled nearly 20% after the closing bell Thursday following an apparent statistical miss in part of a Phase 3 trial for cancer drug ivonescimab, according to Endpoints News. BioPharma Dive characterized the setback as "self-inflicted," noting the company's decision to conduct an interim analysis backfired on investor sentiment. This signals that Summit's strategy of seeking early readouts to accelerate timelines may have come at the cost of statistical power and market confidence.
FDA's ODAC Delivers Split Verdict for AstraZeneca: Camizestrant Rejected 6-3, Truqap Backed 7-1
The FDA's Oncologic Drugs Advisory Committee voted 6-3 against approval of AstraZeneca's camizestrant, an oral SERD for first-line HR-positive, HER2-negative breast cancer with ESR1 mutations, while voting 7-1 in favor of Truqap (capivasertib) for PTEN-deficient metastatic hormone-sensitive prostate cancer, pharmaphorum and BioPharma Dive reported. The panel found insufficient evidence that treating patients with camizestrant at ESR1 mutation detection offers benefit over treatment at radiographic progression, and noted that progression-free survival improvements lacked accompanying overall survival gains. AstraZeneca maintains peak sales projections of $5 billion annually for camizestrant, with SERENA-6 data to be presented at ASCO in late May 2026 and the SERENA-4 trial outcome due late 2026. Regulatory applications remain under review in the EU, Japan, and other markets.
Axsome wins FDA approval for Auvelity in Alzheimer's agitation, challenging Rexulti franchise
Four years after its initial major depressive disorder approval in August 2022, Axsome Therapeutics secured FDA authorization for Auvelity to treat agitation associated with Alzheimer's disease, Endpoints News reported. Fierce Pharma noted the approval positions Auvelity to compete directly with Rexulti in this indication, while Pharmaceutical Technology confirmed the label expansion covers dementia due to Alzheimer's. This move suggests Axsome is building a diversified neuropsychiatric franchise that could significantly expand its commercial footprint beyond depression.
ArchiMed to acquire Esperion Therapeutics in $1.1B take-private transaction
Healthcare investment firm ArchiMed agreed to take cardiovascular drug developer Esperion Therapeutics private in a deal valued at approximately $1.1 billion, reported by Fierce Pharma. The transaction comes shortly after Esperion itself laid out $75 million upfront to acquire Corstasis Therapeutics and its congestive heart failure edema drug Enbumyst, according to the same report. Worth watching because private equity interest in specialty cardiovascular assets suggests confidence in niche cardiology franchises despite broader market volatility.
Moderna Q1 revenues nearly triple to $389M on international COVID vaccine strength
Moderna reported Q1 2026 revenues of $389 million, nearly tripling year-over-year results from the same period in 2025, with international markets driving the increase as pharmaphorum detailed. BioPharma Dive characterized the performance as making up for U.S. vaccine sales declines with better international results, continuing a turnaround that has vaulted the company's stock price in 2026. The move suggests Moderna's geographic diversification strategy is successfully offsetting domestic market saturation in COVID vaccines.
Phase 3 melanoma trial comparing pembrolizumab to physician choice of interferon or ipilimumab remains active
A clinical trial evaluating physician/patient choice of either high-dose recombinant interferon alfa-2B or ipilimumab versus pembrolizumab in treating patients with surgically resected stage III-IV high-risk melanoma is currently in active, not recruiting status, according to ClinicalTrials.gov. The study's design reflects an earlier era of melanoma treatment paradigms now that pembrolizumab has become standard-of-care in many settings.
Hodgkin lymphoma trial testing brentuximab vedotin plus nivolumab against standard therapy actively recruiting
A study comparing standard therapy for Hodgkin lymphoma to the combination of brentuximab vedotin and nivolumab is actively recruiting patients, according to ClinicalTrials.gov. This signals continued interest in checkpoint inhibitor-antibody drug conjugate combinations as potential chemotherapy-sparing regimens in hematologic malignancies.
Saudi Arabia emerges as Middle East clinical trial hub with strong infrastructure investment
Saudi Arabia is developing as a major growth market for clinical trials in the Middle East, underpinned by strong funding and rapidly developing infrastructure, Pharmaceutical Technology reported (sponsored feature). Worth watching because expanding trial geography to the Gulf region could accelerate enrollment timelines and improve representation in pivotal studies for sponsors targeting global approvals.
What to Watch
- Summit's data strategy reassessment — The market's harsh reaction to ivonescimab's interim miss may force sponsors conducting adaptive trials to recalibrate their interim analysis thresholds and communication strategies to avoid similar investor backlash.
- Alzheimer's agitation market competition — With Auvelity now approved, physician uptake dynamics between Axsome's oral agent and Rexulti will determine whether this indication can support multiple branded competitors or consolidates around first-mover advantage.
- Moderna's RSV and flu vaccine pipeline — International COVID vaccine strength buys the company runway, but sustained growth depends on successfully launching its respiratory syncytial virus and influenza franchise in 2026-2027.
- Private equity cardiology consolidation — ArchiMed's Esperion acquisition may signal broader PE interest in acquiring undervalued specialty cardiovascular platforms, potentially triggering additional take-private transactions in the sector.
- AstraZeneca's camizestrant path forward — Despite the 6-3 ODAC rejection, AstraZeneca's $5 billion peak sales projection hinges on SERENA-6 data at ASCO in late May and the SERENA-4 trial readout due late 2026; EU and Japan filings remain active and could yield approvals ahead of any U.S. resubmission.
Market Snapshot
- Checkpoint inhibitor combo landscape: Ongoing trials combining anti-PD-1 agents with antibody-drug conjugates in both solid tumors (melanoma) and hematologic malignancies (Hodgkin lymphoma) reflect industry-wide efforts to improve response rates while reducing chemotherapy exposure.
- Alzheimer's neuropsychiatric symptoms market: With agitation affecting up to 76% of Alzheimer's patients, FDA approvals for both Rexulti and now Auvelity validate the commercial opportunity in behavioral symptoms, which often drive caregiver burden and institutionalization more than cognitive decline alone.
- Geographic trial diversification: Saudi Arabia's emergence as a clinical trial hub reflects broader sponsor interest in Middle Eastern and Asian sites to accelerate enrollment, reduce costs, and meet regulatory requirements for geographic diversity in global dossiers.